p27Kip1(Phospho-Thr187) Antibody

Catalog No: #11208

Package Size: #11208-1 50ul #11208-2 100ul

Orders: order@signalwayantibody.com
Support: tech@signalwayantibody.com

Description

Product Name	p27Kip1(Phospho-Thr187) Antibody
Host Species	Rabbit
Clonality	Polyclonal
Purification	Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy using non-phosphopeptide.
Applications	WB IHC
Species Reactivity	Hu
Specificity	The antibody detects endogenous level of p27Kip1 only when phosphorylated at threonine 187.
Immunogen Type	Peptide-KLH
Immunogen Description	Peptide sequence around phosphorylation site of threonine 187 (E-Q-T(p)-P-K) derived from Human p27Kip1.
Target Name	p27Kip1
Modification	Phospho
Other Names	CDKN1B; CDN1B; Cyclin-dependent kinase inhibitor 1B; Cyclin-dependent kinase inhibitor p27; KIP1
Accession No.	Swiss-Prot: P46527NCBI Protein: NP_004055.1
Concentration	1.0mg/ml
Formulation	Supplied at 1.0mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Storage	Store at -20°C for long term preservation (recommended). Store at 4°C for short term use.

Application Details

Predicted MW: 27kd

Western blotting: 1:500~1:1000

Immunohistochemistry: 1:50~1:100

Images



Western blot analysis of extracts from Hela cells untreated or treated with EGF, IFN-a using p27Kip1(Phospho-Thr187) Antibody #11208.



Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using p27Kip1(Phospho-Thr187) Antibody #11208(left) or the same antibody preincubated with blocking peptide(right).

Background

Important regulator of cell cycle progression. Involved in G1 arrest. Potent inhibitor of cyclin E- and cyclin A-CDK2 complexes. Positive regulator of cyclin D-dependent kinases such as CDK4. Regulated by phosphorylation and degradation events.

Eguchi H, et al. (2003) Cancer Res; 63(15): 4739-46

Le XF, et al. (2003) J Biol Chem;

Connor MK, et al. (2003)

Published Papers

el at., Insights in dynamic kinome reprogramming as a consequence of MEK inhibition in MLL-rearranged AML.In Leukemia on 2014 Mar by K R Kampen, A Ter Elst et al..PMID:24240200, , (2014)

PMID:24240200

Note: This product is for in vitro research use only and is not intended for use in humans or animals.